Family history of prostate cancer should include second- and third-degree relatives
the ONA take:
According to a new study published in the journal The Prostate, researchers from Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, have found that looking at a man's second- and third-degree relatives may be as significant as looking at his first-degree relatives to determine his risk for developing prostate cancer.
Typically, a physician will ask a patient about family members with prostate cancer, and that patient may indicate whether it is a first-degree relative, but researchers wanted to know if second- and third-degree relatives were equally as important to estimate prostate cancer risk for men based on prostate cancer family history. The researchers analyzed data from the Utah Population Database to estimate cancer risk for more than 7.3 million people based on family history.
Results showed that 10% of patients had three times the risk and 26% had two times the risk compared with men with no first-, second-, or third-degree relatives with prostate cancer.
The researchers plan to further investigate the effect of having both a maternal and paternal family history of prostate cancer, as well as other factors, to better calculate cancer risk.
The team is also investigating family history risk assessments for breast and lung cancers. Knowing a patient's family history, and therefore risk for developing cancer, will better determine which patients should receive further screening.
A man's second- and third-degree relatives may be as significant as looking at his first-degree relatives to determine his risk for developing prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|